Shopping Cart
- Remove All
- Your shopping cart is currently empty
PF-07321332 is a potent and orally active inhibitor of SARS-CoV 3C-like protease (3CLPRO) .
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $53 | In Stock | |
2 mg | $75 | In Stock | |
5 mg | $123 | In Stock | |
10 mg | $197 | In Stock | |
25 mg | $349 | In Stock | |
50 mg | $539 | In Stock | |
100 mg | $697 | In Stock | |
200 mg | $995 | In Stock | |
500 mg | $1,490 | In Stock | |
1 mL x 10 mM (in DMSO) | $136 | In Stock |
Description | PF-07321332 is a potent and orally active inhibitor of SARS-CoV 3C-like protease (3CLPRO) . |
In vitro | PF-07321332 is a promising oral antiviral clinical candidate with well-established anti-SARS-CoV-2 activity in vitro. |
In vivo | METHODS: To assay in vivo antiviral activity, Nirmatrelvir (20 mg/kg, 2% DMSO + 20% sulfobutylether-β-cyclodextrin in 0.9% saline) and Molnupiravir (20 mg/kg) were orally administered to SARS-CoV-2 infected K18-hACE2 transgenic mice twice daily for five days. RESULTS: In lethally infected mice, the combination of Nirmatrelvir and Molnupiravir demonstrated severe inhibition of SARS-CoV-2 replication in the lungs and brain and synergistically improved survival by up to 80%. 36% survival was achieved with Nirmatrelvir alone, and 43% with Molnupiravir alone. [3] |
Molecular Weight | 499.53 |
Formula | C23H32F3N5O4 |
Cas No. | 2628280-40-8 |
Smiles | C(N[C@@H](C[C@H]1C(=O)NCC1)C#N)(=O)[C@@H]2[C@@]3([C@@](C3(C)C)(CN2C([C@@H](NC(C(F)(F)F)=O)[C@](C)(C)C)=O)[H])[H] |
Relative Density. | 1.267 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 45 mg/mL (90.08 mM), Sonication is recommended. ![]() | ||||||||||||||||||||||||||||||
In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 13 mg/mL (26.02 mM), In vivo: Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.![]() | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.